Alnylam Pharmaceuticals (ALNY) Current Deferred Revenue (2009 - 2026)

Alnylam Pharmaceuticals has reported Current Deferred Revenue for 18 years, with the latest figure at $3.2 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 88.59% year-over-year to $3.2 million; the trailing twelve-month figure through Mar 2026 stood at $3.2 million (down 88.59% YoY), and the FY2025 full-year result was $4.8 million, down 91.27% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $3.2 million, down from $4.8 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $235.5 million in Q4 2022, with the low at $2.5 million in Q3 2025.
• Historically, Current Deferred Revenue has averaged $65.8 million across 5 years, with a median of $69.0 million in 2024.
• Annual changes were most pronounced in 2024 — Current Deferred Revenue jumped 114.7% — and 2025, when it tumbled 96.42%.
• Alnylam Pharmaceuticals' Current Deferred Revenue stood at $235.5 million in 2022, then sank by 56.37% to $102.8 million in 2023, then sank by 46.01% to $55.5 million in 2024, then tumbled by 91.27% to $4.8 million in 2025, then plunged by 33.68% to $3.2 million in 2026.
• The last three Current Deferred Revenue figures came in at $3.2 million (Q1 2026), $4.8 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.